State Key Laboratory of Oral & Maxillofacial Reconstruction and Regeneration, Key Laboratory of Oral Biomedicine Ministry of Education, Hubei Key Laboratory of Stomatology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430072, China.
Department of Oral & Maxillofacial Head Neck Oncology, School & Hospital of Stomatology, Wuhan University, Wuhan, 430079, Hubei, China.
J Nanobiotechnology. 2024 Mar 29;22(1):135. doi: 10.1186/s12951-024-02408-5.
The deployment of imaging examinations has evolved into a robust approach for the diagnosis of lymph node metastasis (LNM). The advancement of technology, coupled with the introduction of innovative imaging drugs, has led to the incorporation of an increasingly diverse array of imaging techniques into clinical practice. Nonetheless, conventional methods of administering imaging agents persist in presenting certain drawbacks and side effects. The employment of controlled drug delivery systems (DDSs) as a conduit for transporting imaging agents offers a promising solution to ameliorate these limitations intrinsic to metastatic lymph node (LN) imaging, thereby augmenting diagnostic precision. Within the scope of this review, we elucidate the historical context of LN imaging and encapsulate the frequently employed DDSs in conjunction with a variety of imaging techniques, specifically for metastatic LN imaging. Moreover, we engage in a discourse on the conceptualization and practical application of fusing diagnosis and treatment by employing DDSs. Finally, we venture into prospective applications of DDSs in the realm of LNM imaging and share our perspective on the potential trajectory of DDS development.
影像学检查的应用已经发展成为诊断淋巴结转移(LNM)的一种强有力的方法。技术的进步,加上创新的影像学药物的引入,使得越来越多的影像学技术被纳入临床实践。然而,传统的影像学药物给药方法仍然存在某些缺点和副作用。将控释给药系统(DDS)作为输送影像学药物的载体,为改善转移性淋巴结(LN)成像固有的这些局限性提供了一个很有前途的解决方案,从而提高了诊断的准确性。在本综述中,我们阐明了 LN 成像的历史背景,并结合各种影像学技术,特别是针对转移性 LN 成像,介绍了常用的 DDS。此外,我们还讨论了通过使用 DDS 融合诊断和治疗的概念和实际应用。最后,我们探讨了 DDS 在 LNM 成像中的应用前景,并分享了我们对 DDS 发展潜力的看法。
J Nanobiotechnology. 2024-3-29
Pharmacol Res. 2023-12
Research (Wash D C). 2024-9-18
J Control Release. 2023-9
Cancers (Basel). 2023-4-26
Bioconjug Chem. 2023-6-21